[CAS NO. 1672691-50-7] JZP-MA-11
PRODUCTS SPECIFICATIONS [1672691-50-7]
DESCRIPTION [1672691-50-7]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 336.38 |
| Molecular Formula | C15H17FN4O2S |
| SMILES | FC1=CC=C(C=C1)N(C)C(OC2=NSN=C2N3CCCCC3)=O |
Summary
JZP-MA-11 is a positron emission tomography (PET) ligand targeting the endocannabinoid α/β-hydrolase domain 6 (ABHD6) enzyme. JZP-MA-11 selectively inhibits ABHD6 with an IC 50 value of 126 nM. JZP-MA-11 can cross the blood-brain barrier (BBB). [18F]JZP-MA-11 has the potential for preclinical evaluation targeting the brain ABHD6 in mice and nonhuman primate (NHP) [1] .
In Vitro
JZP-MA-11 (10 μM) has no effect on
Forskolin (HY-15371)-stimulated cAMP in HEK293 cells expressing CB
1
or CB
2
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
JZP-MA-11 (1.5 mg/kg; IV; 20 min before tracer injection) results in a decrease in radioactivity uptake in ABHD6-rich organs such as, brain, liver, heart, and kidneys
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | C57BL6 mice (female, 10-12-week-old) [1] |
| Dosage: | 1.5 mg/kg |
| Administration: | IV; 20 min before tracer injection |
| Result: | Resulted in a decrease in radioactivity uptake in ABHD6-rich organs such as, brain, liver, heart, and kidneys. |
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.